News

Media

Conferences

Publications

Clinical

Events

Resources

Hepatitis/MASH

The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.

Latest News

Hepatitis B virus test -- Image credit: gamjai | stock.adobe.com

Study Finds Low Prevalence of HDV Antibody Positivity in Patients With Chronic HBV Infection

By Gillian McGovern, Associate Editor

April 10th 2025

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

Health care professional wiping down contaminated surface -- Image credit: Alla | stock.adobe.com

Aldehyde-Based Surface Disinfectants May Reduce Hepatitis A Virus Transmission, Study Finds

By Gillian McGovern, Associate Editor

April 4th 2025

X-ray image of liver -- Image credit: Sebastian Kaulitzki | stock.adobe.com

BEAM-302 Receives FDA IND Clearance for AATD, a Genetic Disorder Affecting the Liver and Lungs

By Gillian McGovern, Associate Editor

March 31st 2025

Health care professional preparing antigen test -- Image credit: nito | stock.adobe.com

HBcrAg Rapid Diagnostic Test Shows Potential in Timely Detection of HBV DNA Concentrations

By Gillian McGovern, Associate Editor

March 26th 2025

Pharmacist preparing vaccination -- Image credit: PEDROMERINO | stock.adobe.com

Hecolin HEV Vaccination Shows Safety and Immunogenicity in Patients With CHB

By Gillian McGovern, Associate Editor

March 18th 2025

More News

Aspirin May Influence Liver Cancer Development in Hepatitis B

Gail Connor Roche

November 6th 2017

An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.

Vaccine Coverage Among US Children Remains High, But Work to Do

Jennifer Barrett, Assistant Editor

November 3rd 2017

Hepatitis C: A Comprehensive Overview of Effective Treatment Options

Krutika Patel

November 1st 2017

Many new antiviral drugs that treat hepatitis C have similar efficacy, but come with different advantages and disadvantages.

Trending News Today: Request to Reinstate Subsidies Blocked by Federal Court

Laurie Toich, Assistant Editor

October 26th 2017

Top news of the day from across the healthcare landscape.

Trending News Today: Gilead HCV Drug Patents Challenged

Laurie Toich, Assistant Editor

October 26th 2017

Top news of the day from across the healthcare landscape.

Daily Aspirin Reduces Liver Cancer Risk from Hepatitis B

Laurie Toich, Assistant Editor

October 25th 2017

Hepatitis B virus is known to increase the risk of cirrhosis and hepatocellular carcinoma.

Hepatitis C Screening Boosts Efficacy of Opioid Misuse Treatment

Laurie Toich, Assistant Editor

October 25th 2017

A hepatitis C virus diagnosis may curb drug use among those in treatment.

New Drugs Introduced in 2017: Part 3 Genetic Diseases, Hematology, and Liver Disease

Marilyn Bulloch, PharmD, BCPS

October 19th 2017

This year, the FDA is on pace to approve about 38 new medications. Here is a look at 4 of those.

Merck Partners with American Liver Foundation to Educate Veterans About HCV

Laurie Toich, Assistant Editor

October 18th 2017

Veterans may be up to 5 times more likely to have hepatitis C than the general population.

Trending News Today: Senators Take a Short-Term, Bipartisan Approach to Healthcare

Laurie Toich, Assistant Editor

October 18th 2017

Top news of the day from across the healthcare landscape.

Trending News Today: Hepatitis A Death Toll Continues to Climb in San Diego

Laurie Toich, Assistant Editor

October 18th 2017

Top news of the day from across the healthcare landscape.

HCV Treatment Success Not Dependent on Type of Provider

Laurie Toich, Assistant Editor

October 16th 2017

Patients with hepatitis C virus achieve treatment success with specialists, primary care physicians, and nurse practitioners.

Optimizing Drug Plasma Levels Predicts SVR in Hepatitis C Patients

Kenneth Bender

October 13th 2017

The lack of association of SVR with ribavirin dose reflects the wide variance in plasma levels between individuals with hepatitis C receiving the same weight-based dosage.

Hepatitis C Antivirals Safe in Heart Transplant Patients

Gail Connor Roche

October 13th 2017

Heart transplant patients with hepatitis C often cannot not tolerate interferon-based regimens due to cardiac toxicity and other heart-related problems.